| Dr Wilfred Irving Hernandez, MD | |
|
Galeria Pacifico Carr. 10 Km 85.7 Suite 5, Arecibo, PR 00613 | |
| (787) 878-7564 | |
| (787) 878-7218 |
| Full Name | Dr Wilfred Irving Hernandez |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 13 Years |
| Location | Galeria Pacifico Carr. 10 Km 85.7 Suite 5, Arecibo, Puerto Rico |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376896035 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 19539 (Puerto Rico) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gastro-centro Norte Psc | 7618199688 | 2 |
News Archive
An international research collaboration, including Professor IIJIMA Kazumoto et al. (of the Department of Pediatrics, Kobe University Graduate School of Medicine) has revealed that NPHS1 is a disease-susceptibility gene for steroid-sensitive nephrotic syndrome in children.
Polynoma LLC, a U.S. oncology-focused biopharmaceutical company within Hong Kong-based CK Life Sciences Int'l., today announced the start of a Phase III clinical trial program for POL 103A, the Company's novel melanoma vaccine. Polynoma's global, multi-center, double-blind, placebo-controlled Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) is designed to enroll a total of 1059 patients with resected Stage IIb, IIc or III melanoma.
Newer treatments for age-related macular degeneration (AMD)-including an intravitreous (into the eye) injection of a chemotherapy drug and use of a related compound approved for use against the eye disease-do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
ArQule, Inc. today announced the presentation of final results from a Phase 2 clinical trial in non-small cell lung cancer (NSCLC) of ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, at the annual meeting of the European Society for Medical Oncology (ESMO).
Further strengthening its broad line of neurovascular products to treat unruptured brain aneurysms, Covidien plc announced the European launch of its Pipeline™ Flex embolization device at the annual Live Interventional Neuroradiology & Neurosurgery Course (LINNC), held in Paris June 23-25. This next-generation flow diversion device received CE Mark earlier this year.
› Verified 2 days ago
| Entity Name | Gastro-centro Norte Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619394038 PECOS PAC ID: 7618199688 Enrollment ID: O20141106000278 |
News Archive
An international research collaboration, including Professor IIJIMA Kazumoto et al. (of the Department of Pediatrics, Kobe University Graduate School of Medicine) has revealed that NPHS1 is a disease-susceptibility gene for steroid-sensitive nephrotic syndrome in children.
Polynoma LLC, a U.S. oncology-focused biopharmaceutical company within Hong Kong-based CK Life Sciences Int'l., today announced the start of a Phase III clinical trial program for POL 103A, the Company's novel melanoma vaccine. Polynoma's global, multi-center, double-blind, placebo-controlled Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) is designed to enroll a total of 1059 patients with resected Stage IIb, IIc or III melanoma.
Newer treatments for age-related macular degeneration (AMD)-including an intravitreous (into the eye) injection of a chemotherapy drug and use of a related compound approved for use against the eye disease-do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
ArQule, Inc. today announced the presentation of final results from a Phase 2 clinical trial in non-small cell lung cancer (NSCLC) of ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, at the annual meeting of the European Society for Medical Oncology (ESMO).
Further strengthening its broad line of neurovascular products to treat unruptured brain aneurysms, Covidien plc announced the European launch of its Pipeline™ Flex embolization device at the annual Live Interventional Neuroradiology & Neurosurgery Course (LINNC), held in Paris June 23-25. This next-generation flow diversion device received CE Mark earlier this year.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Wilfred Irving Hernandez, MD Laurel Ave 100, Urb. Santa Juanita, Bayamon, PR 00956 Ph: (787) 787-5151 | Dr Wilfred Irving Hernandez, MD Galeria Pacifico Carr. 10 Km 85.7 Suite 5, Arecibo, PR 00613 Ph: (787) 878-7564 |
News Archive
An international research collaboration, including Professor IIJIMA Kazumoto et al. (of the Department of Pediatrics, Kobe University Graduate School of Medicine) has revealed that NPHS1 is a disease-susceptibility gene for steroid-sensitive nephrotic syndrome in children.
Polynoma LLC, a U.S. oncology-focused biopharmaceutical company within Hong Kong-based CK Life Sciences Int'l., today announced the start of a Phase III clinical trial program for POL 103A, the Company's novel melanoma vaccine. Polynoma's global, multi-center, double-blind, placebo-controlled Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) is designed to enroll a total of 1059 patients with resected Stage IIb, IIc or III melanoma.
Newer treatments for age-related macular degeneration (AMD)-including an intravitreous (into the eye) injection of a chemotherapy drug and use of a related compound approved for use against the eye disease-do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
ArQule, Inc. today announced the presentation of final results from a Phase 2 clinical trial in non-small cell lung cancer (NSCLC) of ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, at the annual meeting of the European Society for Medical Oncology (ESMO).
Further strengthening its broad line of neurovascular products to treat unruptured brain aneurysms, Covidien plc announced the European launch of its Pipeline™ Flex embolization device at the annual Live Interventional Neuroradiology & Neurosurgery Course (LINNC), held in Paris June 23-25. This next-generation flow diversion device received CE Mark earlier this year.
› Verified 2 days ago
Francisco Garcia-cortes, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 47 Calle Morell Campos, Arecibo, PR 00612 Phone: 787-878-9300 Fax: 787-879-3372 | |
Juan C Peraza Delgado, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 258 Calle Ventura Gandarilla, Arecibo, PR 00612 Phone: 787-878-4150 | |
Melvyn Acosta-ruiz Sr., MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 53 Calle Domingo Rubio, Arecibo, PR 00612 Phone: 787-878-3304 Fax: 787-878-3304 | |
Jose R Davila-torres, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 53 Calle Andres Garcia, Instituto Del Cancer Y Enfermedades De La Sangre, Arecibo, PR 00612 Phone: 787-817-4973 Fax: 787-817-4997 | |
Luis Rafael Gonzalez, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 58 Ave Barbosa, 58, Arecibo, PR 00612 Phone: 787-878-1908 Fax: 787-878-0421 | |
Mrs. Sandra E Betancourt, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: Urb San Lorenzo Calle Pedro Mora, Suite 1, Arecibo, PR 00612 Phone: 787-817-2512 Fax: 787-816-7364 | |
Dr. Victor Luis Perez-gonzalez, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: Urb Villa Los Santos Calle 16 V 1, Arecibo, PR 00612 Phone: 787-879-1585 |